History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autorinnen und Autoren: Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, Odunsi K, Mayor P, Diergaarde B, Zsiros E, Kelemen LE, Kobel M, Steed H, Defazio A, Jordan SJ, Fasching P, Beckmann M, Risch HA, Rossing MA, Doherty JA, Chang-Claude J, Goodman MT, Doerk T, Edwards R, Modugno F, Ness RB, Matsuo K, Mizuno M, Karlan BY, Goode EL, Kjaer SK, Hogdall E, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LFAG, Sutphen R, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Jensen A, Webb PM, Moysich KB
Zeitschrift: Cancer Epidemiology Biomarkers & Prevention
Jahr der Veröffentlichung: 2017
Band: 26
Heftnummer: 9
Seitenbereich: 1470-1473
ISSN: 1055-9965


Abstract

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR.


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Beckmann, Matthias Prof. Dr.
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe


Einrichtungen weiterer Autorinnen und Autoren

Aichi Cancer Center Research Institute
Brigham and Women's Hospital (BWH)
Cedars-Sinai Medical Center
Danish Cancer Society
Dartmouth College
Deutsches Krebsforschungszentrum (DKFZ)
Fred Hutchinson Cancer Research Center
Independent Health
Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie
Mayo Clinic
Medical University of South Carolina (MUSC)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
New Jersey, Department of Health
QIMR Berghofer Medical Research Institute (früher: the Queensland Institute of Medical Research)
Radboud University Nijmegen
Roswell Park Cancer Institute
Royal Alexandra Hospital (RAH)
Rutgers Cancer Institute of New Jersey
University at Buffalo. State University of New York
University College London (UCL)
University of Calgary
University of California Irvine
University of Michigan
University of New South Wales (UNSW)
University of Pittsburgh
University of Southern California (USC)
University of South Florida (USF)
University of Sydney
University of Texas MD Anderson Cancer Center
University of Virginia (UVA)


Zitierweisen

APA:
Minlikeeva, A.N., Freudenheim, J.L., Eng, K.H., Cannioto, R.A., Friel, G., Szender, J.B.,... Moysich, K.B. (2017). History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention, 26(9), 1470-1473. https://dx.doi.org/10.1158/1055-9965.EPI-17-0367

MLA:
Minlikeeva, Albina N., et al. "History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium." Cancer Epidemiology Biomarkers & Prevention 26.9 (2017): 1470-1473.

BibTeX: 

Zuletzt aktualisiert 2019-11-03 um 11:08